Lanthiopep B.v.

Applied Nanosystems B.v.

Sieger Adriaan Nelemans

Gert Nikolaas Moll

Rick Rink

Antonius Jacobus Marinus Roks

Louwe De Vries

Anneke Kuipers

Leonardus Dorothea Kluskens

Rick Rinck

Marijke Haas

Antonius Jacobus Roks

The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.

Angiotensin type 2 (AT2) receptor agonists and uses thereof

Angiotensin Type 2 (AT2) receptor agonists and uses thereof

The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyrand Proin naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.

Cyclic angiotensin analogs

Growing community of inventors

Leens, Netherlands

Sieger Adriaan Nelemans